Motavizumab biosimilar (MedImmune)

莫维珠单抗生物类似药 (MedImmune)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMotavizumab biosimilar (MedImmune)

Drug Alias Name莫维珠单抗生物仿制药 (MedImmune)莫他韦珠单抗生物仿制药 (MedImmune)MEDI-557

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionRespiratory syncytial virus F protein inhibitors

TargetsRespiratory syncytial virus F protein

Therapy Area/IndicationsRespiratory Syncytial Virus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedimmune Llc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesMedimmune Llc

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus Infections

ATC CodeJ06BB17